TrialCardiovascular diabetology2022

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.

Sok Cin Tye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.